Global Colorectal Cancer Liquid Biopsy Market by End-User (Academics & Research Centers, Diagnostic & Imaging centers, Hospitals), by Biomarker Type (Circulating Tumor Cells, Circulating Tumor DNA, Extracellular Vesicles), by Services (Kits & Reagents, Services, Platforms 7 Instruments) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Up Market Research published a new report titled “Colorectal Cancer Liquid Biopsy Market research report which is segmented by End-User (Academics & Research Centers, Diagnostic & Imaging centers, Hospitals), by Biomarker Type (Circulating Tumor Cells, Circulating Tumor DNA, Extracellular Vesicles), by Services (Kits & Reagents, Services, Platforms 7 Instruments), By Players/Companies MDX Health SA., Guardant Health, Bio-Rad Laboratories Inc., Myriad Genetics, Biocept Inc., F. Hoffmann-La Roche AG, Trovagene Inc., Janssen Diagnostics LLC, NeoLAB, GRAIL, Guardant Health Inc., Qiagen”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Colorectal Cancer Liquid Biopsy Market Research Report |
| By End-User | Academics & Research Centers, Diagnostic & Imaging centers, Hospitals |
| By Biomarker Type | Circulating Tumor Cells, Circulating Tumor DNA, Extracellular Vesicles |
| By Services | Kits & Reagents, Services, Platforms 7 Instruments |
| By Companies | MDX Health SA., Guardant Health, Bio-Rad Laboratories Inc., Myriad Genetics, Biocept Inc., F. Hoffmann-La Roche AG, Trovagene Inc., Janssen Diagnostics LLC, NeoLAB, GRAIL, Guardant Health Inc., Qiagen |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 215 |
| Number of Tables & Figures | 151 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Colorectal Cancer Liquid Biopsy Market Report Segments:
The market is segmented by End-User (Academics & Research Centers, Diagnostic & Imaging centers, Hospitals), by Biomarker Type (Circulating Tumor Cells, Circulating Tumor DNA, Extracellular Vesicles), by Services (Kits & Reagents, Services, Platforms 7 Instruments).
Some of the companies that are profiled in this report are:
- MDX Health SA.
- Guardant Health
- Bio-Rad Laboratories Inc.
- Myriad Genetics
- Biocept Inc.
- F. Hoffmann-La Roche AG
- Trovagene Inc.
- Janssen Diagnostics LLC
- NeoLAB
- GRAIL
- Guardant Health Inc.
- Qiagen
Colorectal Cancer Liquid Biopsy Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Colorectal Cancer Liquid Biopsy Market
Overview of the regional outlook of the Colorectal Cancer Liquid Biopsy Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Colorectal Cancer Liquid Biopsy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Colorectal Cancer Liquid Biopsy Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Academics & Research Centers
2. Diagnostic & Imaging centers
3. Hospitals
7. By Biomarker Type:1. Circulating Tumor Cells
2. Circulating Tumor DNA
3. Extracellular Vesicles
8. By Services:1. Kits & Reagents
2. Services
3. Platforms 7 Instruments
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Colorectal Cancer Liquid Biopsy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Colorectal Cancer Liquid Biopsy Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Colorectal Cancer Liquid Biopsy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Colorectal Cancer Liquid Biopsy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Colorectal Cancer Liquid Biopsy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Colorectal Cancer Liquid Biopsy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Colorectal Cancer Liquid Biopsy Market Size & Forecast, 2018-2028
4.5.1 Colorectal Cancer Liquid Biopsy Market Size and Y-o-Y Growth
4.5.2 Colorectal Cancer Liquid Biopsy Market Absolute $ Opportunity
Chapter 5 Global Colorectal Cancer Liquid Biopsy Market Analysis and Forecast by End-User
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by End-User
5.1.2 Basis Point Share (BPS) Analysis by End-User
5.1.3 Absolute $ Opportunity Assessment by End-User
5.2 Colorectal Cancer Liquid Biopsy Market Size Forecast by End-User
5.2.1 Academics & Research Centers
5.2.2 Diagnostic & Imaging centers
5.2.3 Hospitals
5.3 Market Attractiveness Analysis by End-User
Chapter 6 Global Colorectal Cancer Liquid Biopsy Market Analysis and Forecast by Biomarker Type
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Biomarker Type
6.1.2 Basis Point Share (BPS) Analysis by Biomarker Type
6.1.3 Absolute $ Opportunity Assessment by Biomarker Type
6.2 Colorectal Cancer Liquid Biopsy Market Size Forecast by Biomarker Type
6.2.1 Circulating Tumor Cells
6.2.2 Circulating Tumor DNA
6.2.3 Extracellular Vesicles
6.3 Market Attractiveness Analysis by Biomarker Type
Chapter 7 Global Colorectal Cancer Liquid Biopsy Market Analysis and Forecast by Services
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Services
7.1.2 Basis Point Share (BPS) Analysis by Services
7.1.3 Absolute $ Opportunity Assessment by Services
7.2 Colorectal Cancer Liquid Biopsy Market Size Forecast by Services
7.2.1 Kits & Reagents
7.2.2 Services
7.2.3 Platforms 7 Instruments
7.3 Market Attractiveness Analysis by Services
Chapter 8 Global Colorectal Cancer Liquid Biopsy Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Colorectal Cancer Liquid Biopsy Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Colorectal Cancer Liquid Biopsy Analysis and Forecast
10.1 Introduction
10.2 North America Colorectal Cancer Liquid Biopsy Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Colorectal Cancer Liquid Biopsy Market Size Forecast by End-User
10.6.1 Academics & Research Centers
10.6.2 Diagnostic & Imaging centers
10.6.3 Hospitals
10.7 Basis Point Share (BPS) Analysis by End-User
10.8 Absolute $ Opportunity Assessment by End-User
10.9 Market Attractiveness Analysis by End-User
10.10 North America Colorectal Cancer Liquid Biopsy Market Size Forecast by Biomarker Type
10.10.1 Circulating Tumor Cells
10.10.2 Circulating Tumor DNA
10.10.3 Extracellular Vesicles
10.11 Basis Point Share (BPS) Analysis by Biomarker Type
10.12 Absolute $ Opportunity Assessment by Biomarker Type
10.13 Market Attractiveness Analysis by Biomarker Type
10.14 North America Colorectal Cancer Liquid Biopsy Market Size Forecast by Services
10.14.1 Kits & Reagents
10.14.2 Services
10.14.3 Platforms 7 Instruments
10.15 Basis Point Share (BPS) Analysis by Services
10.16 Absolute $ Opportunity Assessment by Services
10.17 Market Attractiveness Analysis by Services
Chapter 11 Europe Colorectal Cancer Liquid Biopsy Analysis and Forecast
11.1 Introduction
11.2 Europe Colorectal Cancer Liquid Biopsy Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Colorectal Cancer Liquid Biopsy Market Size Forecast by End-User
11.6.1 Academics & Research Centers
11.6.2 Diagnostic & Imaging centers
11.6.3 Hospitals
11.7 Basis Point Share (BPS) Analysis by End-User
11.8 Absolute $ Opportunity Assessment by End-User
11.9 Market Attractiveness Analysis by End-User
11.10 Europe Colorectal Cancer Liquid Biopsy Market Size Forecast by Biomarker Type
11.10.1 Circulating Tumor Cells
11.10.2 Circulating Tumor DNA
11.10.3 Extracellular Vesicles
11.11 Basis Point Share (BPS) Analysis by Biomarker Type
11.12 Absolute $ Opportunity Assessment by Biomarker Type
11.13 Market Attractiveness Analysis by Biomarker Type
11.14 Europe Colorectal Cancer Liquid Biopsy Market Size Forecast by Services
11.14.1 Kits & Reagents
11.14.2 Services
11.14.3 Platforms 7 Instruments
11.15 Basis Point Share (BPS) Analysis by Services
11.16 Absolute $ Opportunity Assessment by Services
11.17 Market Attractiveness Analysis by Services
Chapter 12 Asia Pacific Colorectal Cancer Liquid Biopsy Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Colorectal Cancer Liquid Biopsy Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Colorectal Cancer Liquid Biopsy Market Size Forecast by End-User
12.6.1 Academics & Research Centers
12.6.2 Diagnostic & Imaging centers
12.6.3 Hospitals
12.7 Basis Point Share (BPS) Analysis by End-User
12.8 Absolute $ Opportunity Assessment by End-User
12.9 Market Attractiveness Analysis by End-User
12.10 Asia Pacific Colorectal Cancer Liquid Biopsy Market Size Forecast by Biomarker Type
12.10.1 Circulating Tumor Cells
12.10.2 Circulating Tumor DNA
12.10.3 Extracellular Vesicles
12.11 Basis Point Share (BPS) Analysis by Biomarker Type
12.12 Absolute $ Opportunity Assessment by Biomarker Type
12.13 Market Attractiveness Analysis by Biomarker Type
12.14 Asia Pacific Colorectal Cancer Liquid Biopsy Market Size Forecast by Services
12.14.1 Kits & Reagents
12.14.2 Services
12.14.3 Platforms 7 Instruments
12.15 Basis Point Share (BPS) Analysis by Services
12.16 Absolute $ Opportunity Assessment by Services
12.17 Market Attractiveness Analysis by Services
Chapter 13 Latin America Colorectal Cancer Liquid Biopsy Analysis and Forecast
13.1 Introduction
13.2 Latin America Colorectal Cancer Liquid Biopsy Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Colorectal Cancer Liquid Biopsy Market Size Forecast by End-User
13.6.1 Academics & Research Centers
13.6.2 Diagnostic & Imaging centers
13.6.3 Hospitals
13.7 Basis Point Share (BPS) Analysis by End-User
13.8 Absolute $ Opportunity Assessment by End-User
13.9 Market Attractiveness Analysis by End-User
13.10 Latin America Colorectal Cancer Liquid Biopsy Market Size Forecast by Biomarker Type
13.10.1 Circulating Tumor Cells
13.10.2 Circulating Tumor DNA
13.10.3 Extracellular Vesicles
13.11 Basis Point Share (BPS) Analysis by Biomarker Type
13.12 Absolute $ Opportunity Assessment by Biomarker Type
13.13 Market Attractiveness Analysis by Biomarker Type
13.14 Latin America Colorectal Cancer Liquid Biopsy Market Size Forecast by Services
13.14.1 Kits & Reagents
13.14.2 Services
13.14.3 Platforms 7 Instruments
13.15 Basis Point Share (BPS) Analysis by Services
13.16 Absolute $ Opportunity Assessment by Services
13.17 Market Attractiveness Analysis by Services
Chapter 14 Middle East & Africa (MEA) Colorectal Cancer Liquid Biopsy Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Colorectal Cancer Liquid Biopsy Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Colorectal Cancer Liquid Biopsy Market Size Forecast by End-User
14.6.1 Academics & Research Centers
14.6.2 Diagnostic & Imaging centers
14.6.3 Hospitals
14.7 Basis Point Share (BPS) Analysis by End-User
14.8 Absolute $ Opportunity Assessment by End-User
14.9 Market Attractiveness Analysis by End-User
14.10 Middle East & Africa (MEA) Colorectal Cancer Liquid Biopsy Market Size Forecast by Biomarker Type
14.10.1 Circulating Tumor Cells
14.10.2 Circulating Tumor DNA
14.10.3 Extracellular Vesicles
14.11 Basis Point Share (BPS) Analysis by Biomarker Type
14.12 Absolute $ Opportunity Assessment by Biomarker Type
14.13 Market Attractiveness Analysis by Biomarker Type
14.14 Middle East & Africa (MEA) Colorectal Cancer Liquid Biopsy Market Size Forecast by Services
14.14.1 Kits & Reagents
14.14.2 Services
14.14.3 Platforms 7 Instruments
14.15 Basis Point Share (BPS) Analysis by Services
14.16 Absolute $ Opportunity Assessment by Services
14.17 Market Attractiveness Analysis by Services
Chapter 15 Competition Landscape
15.1 Colorectal Cancer Liquid Biopsy Market: Competitive Dashboard
15.2 Global Colorectal Cancer Liquid Biopsy Market: Market Share Analysis, 2019
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 MDX Health SA.
15.3.2 Guardant Health
15.3.3 Bio-Rad Laboratories Inc.
15.3.4 Myriad Genetics
15.3.5 Biocept Inc.
15.3.6 F. Hoffmann-La Roche AG
15.3.7 Trovagene Inc.
15.3.8 Janssen Diagnostics LLC
15.3.9 NeoLAB
15.3.10 GRAIL
15.3.11 Guardant Health Inc.
15.3.12 Qiagen
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Colorectal Cancer Liquid Biopsy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Colorectal Cancer Liquid Biopsy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Colorectal Cancer Liquid Biopsy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Colorectal Cancer Liquid Biopsy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Colorectal Cancer Liquid Biopsy Market Size & Forecast, 2018-2028
4.5.1 Colorectal Cancer Liquid Biopsy Market Size and Y-o-Y Growth
4.5.2 Colorectal Cancer Liquid Biopsy Market Absolute $ Opportunity
Chapter 5 Global Colorectal Cancer Liquid Biopsy Market Analysis and Forecast by End-User
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by End-User
5.1.2 Basis Point Share (BPS) Analysis by End-User
5.1.3 Absolute $ Opportunity Assessment by End-User
5.2 Colorectal Cancer Liquid Biopsy Market Size Forecast by End-User
5.2.1 Academics & Research Centers
5.2.2 Diagnostic & Imaging centers
5.2.3 Hospitals
5.3 Market Attractiveness Analysis by End-User
Chapter 6 Global Colorectal Cancer Liquid Biopsy Market Analysis and Forecast by Biomarker Type
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Biomarker Type
6.1.2 Basis Point Share (BPS) Analysis by Biomarker Type
6.1.3 Absolute $ Opportunity Assessment by Biomarker Type
6.2 Colorectal Cancer Liquid Biopsy Market Size Forecast by Biomarker Type
6.2.1 Circulating Tumor Cells
6.2.2 Circulating Tumor DNA
6.2.3 Extracellular Vesicles
6.3 Market Attractiveness Analysis by Biomarker Type
Chapter 7 Global Colorectal Cancer Liquid Biopsy Market Analysis and Forecast by Services
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Services
7.1.2 Basis Point Share (BPS) Analysis by Services
7.1.3 Absolute $ Opportunity Assessment by Services
7.2 Colorectal Cancer Liquid Biopsy Market Size Forecast by Services
7.2.1 Kits & Reagents
7.2.2 Services
7.2.3 Platforms 7 Instruments
7.3 Market Attractiveness Analysis by Services
Chapter 8 Global Colorectal Cancer Liquid Biopsy Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Colorectal Cancer Liquid Biopsy Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Colorectal Cancer Liquid Biopsy Analysis and Forecast
10.1 Introduction
10.2 North America Colorectal Cancer Liquid Biopsy Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Colorectal Cancer Liquid Biopsy Market Size Forecast by End-User
10.6.1 Academics & Research Centers
10.6.2 Diagnostic & Imaging centers
10.6.3 Hospitals
10.7 Basis Point Share (BPS) Analysis by End-User
10.8 Absolute $ Opportunity Assessment by End-User
10.9 Market Attractiveness Analysis by End-User
10.10 North America Colorectal Cancer Liquid Biopsy Market Size Forecast by Biomarker Type
10.10.1 Circulating Tumor Cells
10.10.2 Circulating Tumor DNA
10.10.3 Extracellular Vesicles
10.11 Basis Point Share (BPS) Analysis by Biomarker Type
10.12 Absolute $ Opportunity Assessment by Biomarker Type
10.13 Market Attractiveness Analysis by Biomarker Type
10.14 North America Colorectal Cancer Liquid Biopsy Market Size Forecast by Services
10.14.1 Kits & Reagents
10.14.2 Services
10.14.3 Platforms 7 Instruments
10.15 Basis Point Share (BPS) Analysis by Services
10.16 Absolute $ Opportunity Assessment by Services
10.17 Market Attractiveness Analysis by Services
Chapter 11 Europe Colorectal Cancer Liquid Biopsy Analysis and Forecast
11.1 Introduction
11.2 Europe Colorectal Cancer Liquid Biopsy Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Colorectal Cancer Liquid Biopsy Market Size Forecast by End-User
11.6.1 Academics & Research Centers
11.6.2 Diagnostic & Imaging centers
11.6.3 Hospitals
11.7 Basis Point Share (BPS) Analysis by End-User
11.8 Absolute $ Opportunity Assessment by End-User
11.9 Market Attractiveness Analysis by End-User
11.10 Europe Colorectal Cancer Liquid Biopsy Market Size Forecast by Biomarker Type
11.10.1 Circulating Tumor Cells
11.10.2 Circulating Tumor DNA
11.10.3 Extracellular Vesicles
11.11 Basis Point Share (BPS) Analysis by Biomarker Type
11.12 Absolute $ Opportunity Assessment by Biomarker Type
11.13 Market Attractiveness Analysis by Biomarker Type
11.14 Europe Colorectal Cancer Liquid Biopsy Market Size Forecast by Services
11.14.1 Kits & Reagents
11.14.2 Services
11.14.3 Platforms 7 Instruments
11.15 Basis Point Share (BPS) Analysis by Services
11.16 Absolute $ Opportunity Assessment by Services
11.17 Market Attractiveness Analysis by Services
Chapter 12 Asia Pacific Colorectal Cancer Liquid Biopsy Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Colorectal Cancer Liquid Biopsy Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Colorectal Cancer Liquid Biopsy Market Size Forecast by End-User
12.6.1 Academics & Research Centers
12.6.2 Diagnostic & Imaging centers
12.6.3 Hospitals
12.7 Basis Point Share (BPS) Analysis by End-User
12.8 Absolute $ Opportunity Assessment by End-User
12.9 Market Attractiveness Analysis by End-User
12.10 Asia Pacific Colorectal Cancer Liquid Biopsy Market Size Forecast by Biomarker Type
12.10.1 Circulating Tumor Cells
12.10.2 Circulating Tumor DNA
12.10.3 Extracellular Vesicles
12.11 Basis Point Share (BPS) Analysis by Biomarker Type
12.12 Absolute $ Opportunity Assessment by Biomarker Type
12.13 Market Attractiveness Analysis by Biomarker Type
12.14 Asia Pacific Colorectal Cancer Liquid Biopsy Market Size Forecast by Services
12.14.1 Kits & Reagents
12.14.2 Services
12.14.3 Platforms 7 Instruments
12.15 Basis Point Share (BPS) Analysis by Services
12.16 Absolute $ Opportunity Assessment by Services
12.17 Market Attractiveness Analysis by Services
Chapter 13 Latin America Colorectal Cancer Liquid Biopsy Analysis and Forecast
13.1 Introduction
13.2 Latin America Colorectal Cancer Liquid Biopsy Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Colorectal Cancer Liquid Biopsy Market Size Forecast by End-User
13.6.1 Academics & Research Centers
13.6.2 Diagnostic & Imaging centers
13.6.3 Hospitals
13.7 Basis Point Share (BPS) Analysis by End-User
13.8 Absolute $ Opportunity Assessment by End-User
13.9 Market Attractiveness Analysis by End-User
13.10 Latin America Colorectal Cancer Liquid Biopsy Market Size Forecast by Biomarker Type
13.10.1 Circulating Tumor Cells
13.10.2 Circulating Tumor DNA
13.10.3 Extracellular Vesicles
13.11 Basis Point Share (BPS) Analysis by Biomarker Type
13.12 Absolute $ Opportunity Assessment by Biomarker Type
13.13 Market Attractiveness Analysis by Biomarker Type
13.14 Latin America Colorectal Cancer Liquid Biopsy Market Size Forecast by Services
13.14.1 Kits & Reagents
13.14.2 Services
13.14.3 Platforms 7 Instruments
13.15 Basis Point Share (BPS) Analysis by Services
13.16 Absolute $ Opportunity Assessment by Services
13.17 Market Attractiveness Analysis by Services
Chapter 14 Middle East & Africa (MEA) Colorectal Cancer Liquid Biopsy Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Colorectal Cancer Liquid Biopsy Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Colorectal Cancer Liquid Biopsy Market Size Forecast by End-User
14.6.1 Academics & Research Centers
14.6.2 Diagnostic & Imaging centers
14.6.3 Hospitals
14.7 Basis Point Share (BPS) Analysis by End-User
14.8 Absolute $ Opportunity Assessment by End-User
14.9 Market Attractiveness Analysis by End-User
14.10 Middle East & Africa (MEA) Colorectal Cancer Liquid Biopsy Market Size Forecast by Biomarker Type
14.10.1 Circulating Tumor Cells
14.10.2 Circulating Tumor DNA
14.10.3 Extracellular Vesicles
14.11 Basis Point Share (BPS) Analysis by Biomarker Type
14.12 Absolute $ Opportunity Assessment by Biomarker Type
14.13 Market Attractiveness Analysis by Biomarker Type
14.14 Middle East & Africa (MEA) Colorectal Cancer Liquid Biopsy Market Size Forecast by Services
14.14.1 Kits & Reagents
14.14.2 Services
14.14.3 Platforms 7 Instruments
14.15 Basis Point Share (BPS) Analysis by Services
14.16 Absolute $ Opportunity Assessment by Services
14.17 Market Attractiveness Analysis by Services
Chapter 15 Competition Landscape
15.1 Colorectal Cancer Liquid Biopsy Market: Competitive Dashboard
15.2 Global Colorectal Cancer Liquid Biopsy Market: Market Share Analysis, 2019
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 MDX Health SA.
15.3.2 Guardant Health
15.3.3 Bio-Rad Laboratories Inc.
15.3.4 Myriad Genetics
15.3.5 Biocept Inc.
15.3.6 F. Hoffmann-La Roche AG
15.3.7 Trovagene Inc.
15.3.8 Janssen Diagnostics LLC
15.3.9 NeoLAB
15.3.10 GRAIL
15.3.11 Guardant Health Inc.
15.3.12 Qiagen
Segments Covered in the Report
The global Colorectal Cancer Liquid Biopsy market has been segmented based on
By End-User
The global Colorectal Cancer Liquid Biopsy market has been segmented based on
By End-User
- Academics & Research Centers
- Diagnostic & Imaging centers
- Hospitals
- Circulating Tumor Cells
- Circulating Tumor DNA
- Extracellular Vesicles
- Kits & Reagents
- Services
- Platforms 7 Instruments
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- MDX Health SA.
- Guardant Health
- Bio-Rad Laboratories Inc.
- Myriad Genetics
- Biocept Inc.
- F. Hoffmann-La Roche AG
- Trovagene Inc.
- Janssen Diagnostics LLC
- NeoLAB
- GRAIL
- Guardant Health Inc.
- Qiagen
Our Clients
Related Reports
Some other reports from this category!
